Which Turnaround Is Better for Retirees: CVS or INTC?
Both CVS and Intel delivered real turnaround results in 2026, then both stocks got punished for very different reasons. For a retiree drawing income from a portfolio, one of those reasons matters far more than the other.
Should a retirement-focused investor own CVS Health (NYSE:CVS | CVS Price Prediction) or Intel (NASDAQ:INTC)? Both turnarounds delivered measurable results in 2026, and both stocks sold off hard in the past month for different reasons. Intel was punished for execution doubt around its 18A process node roadmap. CVS was punished for a preliminary 2027 forecast. Which setback matters more for a portfolio that needs to fund withdrawals?
Did the Turnaround Actually Deliver?
Both did. Intel posted 25.42% year-over-year revenue growth in Q2 2026, described by CEO Lip-Bu Tan as “the strongest revenue growth in more than fifteen years.” Data Center and AI revenue grew 59% year over year to $6.26 billion, and Intel Foundry revenue reached $5.76 billion, up 31%, though Foundry still ran a $2.1 billion quarterly operating loss. The re-rating has tied to 18A shipments, a roughly $5 billion Nvidia equity investment, and a Google AI chip foundry order.
CVS delivered more quietly. Q2 2026 adjusted EPS came in at $2.58 on revenue of more than $106 billion. Management raised full-year adjusted EPS guidance to $7.90 to $8.10 and full-year operating cash flow to at least $11.5 billion. CEO David Joyner said CVS had delivered “more than $2 billion of year over year improvement in adjusted operating income” so far in 2026.
⇒ The winner here is Intel, on raw magnitude of operational improvement.
Why Each Sold Off
Intel’s setback goes to the thesis itself: concerns about 18A timing and competitive pressure from AMD in data center threaten the manufacturing roadmap the re-rating rests on. If the foundry ramp slips, the recovery loses its foundation. Tan acknowledged, “Some area we are still behind, but we are catching up very fast.”
CVS’s setback concerns a forecast. Reuters and Bloomberg reported in early August 2026 that shares fell after preliminary 2027 commentary disappointed, even though the reported quarter beat. Management pegged a floor for 2027 adjusted EPS at $8.44, citing 340B program pressure and a more disciplined selling season. GuruFocus flagged CVS as overvalued on its own value measure in mid-August 2026. A guidance signal can foreshadow deterioration, but it concerns a year that has not begun.
⇒ The winner is CVS, because a 2027 forecast is more revisable than a manufacturing roadmap.
What You Are Paid to Wait
For a retiree, this dimension decides the argument. CVS pays a quarterly dividend of $0.665, an annualized $2.66, with a dividend yield of 2.9%. Shares closed at $94.32 on August 26, 2026, on a trailing P/E of 25 and forward P/E of 12, with beta of 0.596.
Intel pays nothing. The dividend was cut to $0.125 and later suspended; the last recorded payment was in September 2024. Intel is not profitable on a trailing basis, so no earnings multiple applies. Shares closed at $88.24 on August 26, 2026, up 262.4% over the trailing year, with a beta of 2.241. A new buyer today purchases the recovery that has already happened, with no income while waiting.
⇒ The winner is CVS, decisively.
Verdict for Retirement Investors
CVS wins for a retirement-focused investor. The setback concerns a forecast for a year that has not begun, against an operating business with real earnings, a 2.9% dividend, and low beta (the case for building income you never have to sell out of is the whole subject of our free dividend ladder guide, here). Intel asks the holder to accept no income, no trailing profitability, entry after a 262.4% one-year run, and an execution risk that just surfaced.
This is a judgment about suitability rather than a forecast of relative price performance. Intel has been the better stock over the past year and could remain so. A younger investor with a longer horizon might reasonably choose Intel’s re-rating story over CVS’s dividend and cash flow. For someone drawing down a portfolio, that trade is the wrong one.
There are two checkpoints to watch. For Intel, evidence on 18A timing and whether foundry customer commitments convert into disclosed external revenue beyond the current $293 million quarterly run rate. For CVS, whether the 2027 outlook is revised as the year approaches and whether Health Care Benefits holds its Q2 medical benefit ratio of 87.4%.
Contact [email protected] for any questions or corrections.
Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.
Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.
Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.
Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.
